Combination treatment shows benefits in rare, aggressive kidney cancer
Fumarate hydratase (FH)-deficient renal cell carcinoma (RCC) is a rare [...]
Circulating tumour DNA (ctDNA) as a test for kidney cancer
When a tumour grows it 'sheds' small pieces of tumour [...]
Comparison of real-world outcomes from combination therapies for advanced kidney cancer
Direct comparisons of combination treatments for previously untreated, advanced kidney [...]
Pembrolizumab plus axitinib shows sustained benefit in advanced kidney cancer
The final long-term follow-up data from the phase 3 KEYNOTE-426 [...]
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line treatment for metastatic kidney cancer
Treatment of advanced (metastatic) kidney cancer has improved considerably over [...]
Metastasis-Directed Radiotherapy Shows Improved Kidney Cancer Outcomes
A recent phase 2 clinical trial presented at the 2025 [...]
NHS England Cancer Patient Experience Survey 2024
Every year, the NHS in England finds out what cancer [...]
Government publishes NHS 10-year Health Plan
According to a recent investigation by Lord Darzi, the NHS [...]
Screening programme to be extended to Wakefield
Hundreds of people in Wakefield and across the region will [...]
Cabozantinib most promising for refractory metastatic kidney cancer
In a European study of second-line treatments for metastatic kidney [...]
